ANALYSIS OF THE USE OF BEVACIZUMAB FOR THE TREATMENT OF GLIOBLASTOMA IN THE UNITED STATES

被引：0
|
作者：
Garcia, Catherine [1 ]
Chitwood, Holly [1 ]
Harwood, Christopher [1 ]
Shelton, Brent [1 ]
Morgan, Rachael [1 ]
Vermuelen, Lee [1 ]
Villano, John [1 ]
机构：
[1] Univ Kentucky, Lexington, KY USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EPID-17
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [21] Geographic Disparities in Access to Glioblastoma Treatment Based on Hispanic Ethnicity in the United States
    Lu, Victor M.
    Shah, Ashish H.
    Eichberg, Daniel G.
    Komotar, Ricardo J.
    Ivan, Michael E.
    [J]. NEUROSURGERY, 2020, 67 : 60 - 61
  • [22] Molecular analysis of a recurrent glioblastoma treated with bevacizumab
    Furuta, Takuya
    Nakada, Mitsutoshi
    Misaki, Kouichi
    Sato, Yasunori
    Hayashi, Yutaka
    Nakanuma, Yasuni
    Hamada, Jun-ichiro
    [J]. BRAIN TUMOR PATHOLOGY, 2014, 31 (01) : 32 - 39
  • [23] Bevacizumab for glioblastoma
    Narita, Yoshitaka
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1759 - 1765
  • [24] Molecular analysis of a recurrent glioblastoma treated with bevacizumab
    Takuya Furuta
    Mitsutoshi Nakada
    Kouichi Misaki
    Yasunori Sato
    Yutaka Hayashi
    Yasuni Nakanuma
    Jun-ichiro Hamada
    [J]. Brain Tumor Pathology, 2014, 31 : 32 - 39
  • [25] Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis
    Kesselheim, Jennifer C.
    Norden, Andrew D.
    Wen, Patrick Y.
    Joffe, Steven
    [J]. ONCOLOGIST, 2011, 16 (10): : 1435 - 1439
  • [26] Treatment expansion for opioid use disorders in the United States
    Parrino, Mark
    [J]. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2018, 20 (01) : 5 - 6
  • [27] Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
    Chen, Zhaoyan
    Zhan, Mei
    Tian, Fangyuan
    Xu, Ting
    [J]. ONCOLOGY LETTERS, 2020, 19 (01) : 424 - 430
  • [28] Efficacy analysis of bevacizumab combined with radiotherapy in the treatment of glioblastoma and its impact on immune function
    Xu, Changyong
    Song, Qingyue
    Wang, Xiaofei
    Liu, Liping
    Yu, Qingqing
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 : S393 - S393
  • [29] GLIOBLASTOMA TREATMENT OF BEVACIZUMAB ERA IN KANSAI REGION, JAPAN
    Mori, Kanji
    Shofuda, Tomoko
    Okita, Yoshiko
    Arita, Hideyuki
    Kinoshita, Manabu
    Terakawa, Yuzo
    Tsuyuguchi, Naohiro
    Tomogane, Yusuke
    Fukai, Junya
    Ishibashi, Kenichi
    Nishida, Namiko
    Taki, Takuyu
    Nonaka, Masahiro
    Izumoto, Shuichi
    Moriuchi, Shusuke
    Nakajima, Yoshikazu
    Hashimoto, Naoya
    Kodama, Yoshinori
    Hirose, Takanori
    Kanemura, Yonehiro
    [J]. NEURO-ONCOLOGY, 2017, 19 : 68 - 69
  • [30] Bevacizumab and Other Targeted Agents in the Upfront Treatment of Glioblastoma
    Clarke, Jennifer L.
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2014, 24 (04) : 273 - 278
12345